[1] 芮 雪,范晓华,潘卫萍.脑卒中后抑郁发生率及其相关因素的调查分析[J].医学信息,2012,23(6):1939-1940.
[2] Johnson JL Minaik PA Nystrom KV,et al.Poststroke depression incidence and risk factors: an intergrave literature review[J].J Neurosci Nurs,2006,38(4 Suppl):316-327.
[3] Jia H,Damush TM,Qin H,et al.The impact of poststroke depression on healthcare use by veterans with acute stroke[J].Stroke,2006,37:2796-2801.
[4] Begre S,Traber M,Gerber M,et al.Change in pain severity with open label yenlafaxine use in patients with a depressive symptomatology: an observational study in primary care[J].Eur Psychiatr,2008,23(3):178-186.
[5] 金卫东,冯 斌.文拉法辛治疗抑郁症的循证医学证据[J].四川精神卫生,2005,18(1):64.
[6] 中华神经科学会,中华神经外科学会.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379.
[7] 世界卫生组织. ICD-10精神与行为障碍分类[M].北京:人民卫生出版社,1993:54.
[8] 周国平,李 丹.脑卒中后抑郁的相关因素调查[J].中国误诊学杂志,2009,9(31):7807.
[9] 沈渔邨. 精神病学[M].5版.北京:人民卫生出版社,2009:857.
[10] 彭代辉,黄 佳.文拉法辛缓释片与文拉法辛缓释胶囊治疗抑郁症的随机、双盲对照研究[J].中国新药与临床杂志,2013,32(4):322.